AG
ACAD icon

Algert Global’s Acadia Pharmaceuticals ACAD Stock Holding History

Algert Global’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-140,462
Closed -$3.13M – 1235
2026
Q1 		$3.13M Sell
140,462
-473,948
-77% -$11.3M 0.05% 586
2025
Q4 		$16.4M Buy
614,410
+214,301
+54% +$5.12M 0.26% 90
2025
Q3 		$8.54M Buy
400,109
+347,017
+654% +$8.21M 0.14% 231
2025
Q2 		$1.15M Sell
53,092
-296,612
-85% -$5.51M 0.02% 780
2025
Q1 		$5.81M Sell
349,704
-136,200
-28% -$2.47M 0.14% 223
2024
Q4 		$8.92M Sell
485,904
-63,552
-12% -$1.03M 0.21% 139
2024
Q3 		$8.45M Buy
549,456
+15,313
+3% +$255K 0.23% 113
2024
Q2 		$8.68M Buy
534,143
+179,799
+51% +$2.9M 0.29% 64
2024
Q1 		$6.55M Buy
354,344
+93,467
+36% +$2.32M 0.26% 96
2023
Q4 		$8.17M Buy
260,877
+149,343
+134% +$3.57M 0.33% 50
2023
Q3 		$2.32M Buy
111,534
+380
+0.3% +$10.3K 0.11% 313
2023
Q2 		$2.66M Sell
111,154
-30,510
-22% -$678K 0.12% 286
2023
Q1 		$2.67M Sell
141,664
-32,855
-19% -$626K 0.13% 248
2022
Q4 		$2.78M Sell
174,519
-3,193
-2% -$49.9K 0.15% 195
2022
Q3 		$2.91M Buy
177,712
+11,581
+7% +$188K 0.18% 162
2022
Q2 		$2.34M Buy
166,131
+62,079
+60% +$1.16M 0.18% 141
2022
Q1 		$2.52M Buy
104,052
+67,620
+186% +$1.64M 0.17% 157
2021
Q4 		$850K Buy
36,432
+16,370
+82% +$329K 0.11% 326
2021
Q3 		$333K Buy
+20,062
New +$387K 0.04% 718
2021
Q1 		– Sell
-6,897
Closed -$369K – 428
2020
Q4 		$369K Hold
6,897
– – 0.11% 268
2020
Q3 		$285K Sell
6,897
-5,040
-42% -$218K 0.09% 265
2020
Q2 		$579K Sell
11,937
-11,672
-49% -$560K 0.2% 166
2020
Q1 		$997K Buy
+23,609
New +$973K 0.42% 71
2019
Q4 		– Sell
-7,370
Closed -$265K – 374
2019
Q3 		$265K Buy
+7,370
New +$223K 0.1% 236

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Algert Global's ACAD Position: Q2 2026 in Review

Algert Global sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 140,462 shares — an estimated $3.13M sold.

Algert Global first reported a position in ACAD in Q3 2019 and held it in 24 quarters. The position peaked at $16.4M in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Algert Global reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Algert Global sold 140,462 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.13M.
  • Algert Global first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 24 quarters.
  • Algert Global's Acadia Pharmaceuticals position peaked at $16.4M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.